NWPF

News ArchivesRead News

Amarantus BioSciences Licenses Parkinson's Disease Diagnostic Biomarker Test from Power3 Medical Products

Monday January 23, 2012

Amarantus BioSciences, Inc

Business Wire - UNNYVALE, Calif. & THE WOODLANDS, Texas, Jan 23, 2012 (BUSINESS WIRE) -- Amarantus BioSciences, Inc. AMBS , a biotechnology company developing MANF, a first-in-class disease--modifying therapeutic protein being developed for the treatment of Parkinson's Disease, today announced an exclusive worldwide license agreement with Power3 Medical Products, Inc. for the NuroPro(R) Blood Test as it relates to Parkinson's disease diagnosis. Concurrent with the license, Amarantus has raised $100,000 from a private, foreign investor introduced to the Company by www.tomorrowsbluechips.com.

The NuroPro Blood Test is Power3's diagnostic platform for the early detection of neurodegenerative diseases. It is being developed as a tool to assist physicians to more accurately diagnose disease and monitor progression. The platform involves monitoring the concentration of 57 protein markers in blood serum identified to be linked to neurodegeneration in order to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Amarantus' license is focused on the further development of a subset of 21 of these protein markers specifically targeting early diagnosis and ongoing monitoring of Parkinson's disease.

The Parkinson's disease application of the NuroPro Blood Test has completed proof-of-concept and Phase 1 clinical validation studies. Amarantus plans to initiate a Phase 2 clinical validation study in the first half of 2012 that is expected to last approximately six months. Management of the trial will be partnered to Power3 as part of its ongoing strategy to build its Clinical Research Organization business unit.

"The in-license of the NuroPro Blood Test for Parkinson's disease expands our product offering as we strive to become the leader in the evaluation and treatment of Parkinson's disease," said Gerald Commissioning, President and CEO of Amarantus BioSciences. "Now that we will be able to tailor our therapeutic development pathway towards a companion diagnostic product that we control, Amarantus is positioned to build a strategic advantage over competitors as the execution of our clinical and regulatory strategy continues to advance MANF as a disease-modifying treatment for Parkinson's disease. The Company was also recently awarded the composition of matter patent for MANF by the US Patent & Trademark Office, further enhancing our position in the field."

Given the length of time it takes to accurately diagnose Parkinson's disease and the relatively high early misdiagnosis rates, the development of a blood-based biomarker test is likely to generate significant interest among neurologists and primary care physicians as it will allow them to intervene at an earlier stage in disease progression. In addition, the NuroPro Blood test for Parkinson's may generate partnering and revenue opportunities for Amarantus.

The terms of the agreement give Amarantus an exclusive license to develop, manufacture, have manufactured, use, market, sell and import medical devices and methods under the Power3 Parkinson's Disease Intellectual Property (IP). In addition, the license provides Amarantus an exclusive, royalty-free, fully paid-up worldwide license to Power3 know-how, patents and patent applications which relate to medical devices and methods for the treatment of neurodegenerative disease as it relates to Parkinson's disease.

Amarantus paid a $25,000 exclusivity fee in common stock on November 11, 2011 and will issue to Power3 $475,000 worth of common stock. In addition, Amarantus has an option to purchase all of the Parkinson's Disease IP owned by Power3 for $500,000 worth of common stock and maintains a Right of First Refusal to acquire the balance of the NuroPro platform for Alzheimer's, ALS and all other neurodegenerative diseases. The initial term of this License Agreement is for one year and is renewable upon mutual written agreement of the parties.

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

SOURCE: Amarantus BioSciences, Inc.

http://www.marketwatch.com/story/amarantus-biosciences-licenses-parkinsons-disease-diagnostic-biomarker-test-from-power3-medical-products-2012-01-23

Recent News

Aug 24 - Study Details Process Involved in Parkinson’s Disease
Aug 20 - Two proteins work together to help cells eliminate trash; Parkinson's may result
Aug 17 - Scientists visualize critical part of basal ganglia pathways
Aug 17 - VA benefits office seeks all vets exposed to Agent Orange
Aug 12 - New, rapid dementia screening tool rivals 'gold standard' clinical evaluations
Aug 11 - Strolling in Seaside, fighting Parkinson's
Aug 11 - Scientists probing molecular origins of Parkinson's disease highlight two proteins
Aug 11 - Could Chocolate Help To Ease Parkinson’s Disease?
Aug 10 - Take 2: Why Seattle should try to replicate Spokane’s 3-on-3 Hoopfest success
Aug 10 - Book Review: A voyage into Parkinson’s disease, led by patient and journalist
Aug 10 - Parkinson's could be slowed with existing drug
Aug 7 - Opinion: Why modern life is making dementia in your 40s more likely
Aug 3 - Software Turns Smartphones into Tools for Medical Research
Jul 31 - Innovative Technology Using Dragonflies Might Offer Insights Into Human Brain Function
Jul 27 - Low-dose lithium reduces side effects from most common treatment for Parkinson's disease
Jul 27 - Opinion: Parkinson's disease creating class of workers who fear for their jobs: PennLive letters
Jul 22 - Parkinson's: Diabetes drug may offer clue to treatment
Jul 19 - Alzheimer's Drugs in the Works Might Treat Other Diseases, Too
Jul 17 - Parkinson's disease may be treatable with antimalaria drugs
Jul 16 - Virtual research studies feasible